258 related articles for article (PubMed ID: 30003670)
1. Glycaemic control and mortality in older people with type 2 diabetes: The Fremantle Diabetes Study Phase II.
Bruce DG; Davis WA; Davis TME
Diabetes Obes Metab; 2018 Dec; 20(12):2852-2859. PubMed ID: 30003670
[TBL] [Abstract][Full Text] [Related]
2. Early glycaemic control among patients with type 2 diabetes and initial glucose-lowering treatment: a 13-year population-based cohort study.
Thomsen RW; Baggesen LM; Svensson E; Pedersen L; Nørrelund H; Buhl ES; Haase CL; Johnsen SP
Diabetes Obes Metab; 2015 Aug; 17(8):771-80. PubMed ID: 25929277
[TBL] [Abstract][Full Text] [Related]
3. A randomized controlled trial of the efficacy and safety of saxagliptin as add-on therapy in patients with type 2 diabetes and inadequate glycaemic control on metformin plus a sulphonylurea.
Moses RG; Kalra S; Brook D; Sockler J; Monyak J; Visvanathan J; Montanaro M; Fisher SA
Diabetes Obes Metab; 2014 May; 16(5):443-50. PubMed ID: 24205943
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of once-weekly dulaglutide versus insulin glargine in mainly Asian patients with type 2 diabetes mellitus on metformin and/or a sulphonylurea: A 52-week open-label, randomized phase III trial.
Wang W; Nevárez L; Filippova E; Song KH; Tao B; Gu L; Wang F; Li P; Yang J
Diabetes Obes Metab; 2019 Feb; 21(2):234-243. PubMed ID: 30129089
[TBL] [Abstract][Full Text] [Related]
5. Glycaemic control among patients with type 2 diabetes mellitus in seven European countries: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) study.
Alvarez Guisasola F; Mavros P; Nocea G; Alemao E; Alexander CM; Yin D
Diabetes Obes Metab; 2008 Jun; 10 Suppl 1():8-15. PubMed ID: 18435669
[TBL] [Abstract][Full Text] [Related]
6. Insulin in type 2 diabetes: a useful alternative despite limited assessment based on surrogate endpoints.
Prescrire Int; 2005 Oct; 14(79):187-93. PubMed ID: 16285076
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea.
Lukashevich V; Del Prato S; Araga M; Kothny W
Diabetes Obes Metab; 2014 May; 16(5):403-9. PubMed ID: 24199686
[TBL] [Abstract][Full Text] [Related]
8. Effect of diabetes duration on the relationship between glycaemic control and risk of death in older adults with type 2 diabetes.
Ghouse J; Isaksen JL; Skov MW; Lind B; Svendsen JH; Kanters JK; Olesen MS; Holst AG; Nielsen JB
Diabetes Obes Metab; 2020 Feb; 22(2):231-242. PubMed ID: 31596048
[TBL] [Abstract][Full Text] [Related]
9. Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus.
Hemmingsen B; Sonne DP; Metzendorf MI; Richter B
Cochrane Database Syst Rev; 2016 Oct; 10(10):CD012151. PubMed ID: 27749986
[TBL] [Abstract][Full Text] [Related]
10. Long-term sustainability of glycaemic achievements with second-line antidiabetic therapies in patients with type 2 diabetes: A real-world study.
Montvida O; Shaw JE; Blonde L; Paul SK
Diabetes Obes Metab; 2018 Jul; 20(7):1722-1731. PubMed ID: 29536608
[TBL] [Abstract][Full Text] [Related]
11. A retrospective cross-sectional study of type 2 diabetes overtreatment in patients admitted to the geriatric ward.
Wojszel ZB; Kasiukiewicz A
BMC Geriatr; 2019 Sep; 19(1):242. PubMed ID: 31477024
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of gemigliptin, a dipeptidyl peptidase-4 inhibitor, in patients with type 2 diabetes mellitus inadequately controlled with combination treatment of metformin and sulphonylurea: a 24-week, multicentre, randomized, double-blind, placebo-controlled study (TROICA study).
Ahn CH; Han KA; Yu JM; Nam JY; Ahn KJ; Oh TK; Lee HW; Lee DH; Kim J; Chung CH; Park TS; Kim BJ; Park SW; Park HK; Lee KJ; Kim SW; Park JH; Ko KP; Kim CH; Lee H; Jang HC; Park KS
Diabetes Obes Metab; 2017 May; 19(5):635-643. PubMed ID: 28026912
[TBL] [Abstract][Full Text] [Related]
13. Hypoglycaemia in the over 75s: Understanding the predisposing factors in type 2 diabetes (T2DM).
Heald AH; Anderson SG; Cortes GJ; Cholokova V; Narajos M; Khan A; Donnahey G; Livingston M
Prim Care Diabetes; 2018 Apr; 12(2):133-138. PubMed ID: 28941578
[TBL] [Abstract][Full Text] [Related]
14. Addition of sulphonylurea to metformin does not relevantly change body weight: a prospective observational cohort study (ZODIAC-39).
Schrijnders D; Wever R; Kleefstra N; Houweling ST; van Hateren KJ; de Bock GH; Bilo HJ; Groenier KH; Landman GW
Diabetes Obes Metab; 2016 Oct; 18(10):973-9. PubMed ID: 27265756
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study.
Owens DR; Swallow R; Dugi KA; Woerle HJ
Diabet Med; 2011 Nov; 28(11):1352-61. PubMed ID: 21781152
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of insulin degludec/liraglutide (IDegLira) added to sulphonylurea alone or to sulphonylurea and metformin in insulin-naïve people with Type 2 diabetes: the DUAL IV trial.
Rodbard HW; Bode BW; Harris SB; Rose L; Lehmann L; Jarlov H; Thurman J;
Diabet Med; 2017 Feb; 34(2):189-196. PubMed ID: 27589252
[TBL] [Abstract][Full Text] [Related]
17. Mean HbA
Forbes A; Murrells T; Mulnier H; Sinclair AJ
Lancet Diabetes Endocrinol; 2018 Jun; 6(6):476-486. PubMed ID: 29674135
[TBL] [Abstract][Full Text] [Related]
18. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
19. Increased mortality in Type II diabetic patients using sulphonylurea and metformin in combination: a population-based observational study.
Olsson J; Lindberg G; Gottsäter M; Lindwall K; Sjöstrand A; Tisell A; Melander A
Diabetologia; 2000 May; 43(5):558-60. PubMed ID: 10855529
[TBL] [Abstract][Full Text] [Related]
20. Durability and tolerability of dapagliflozin over 52 weeks as add-on to metformin and sulphonylurea in type 2 diabetes.
Matthaei S; Bowering K; Rohwedder K; Sugg J; Parikh S; Johnsson E;
Diabetes Obes Metab; 2015 Nov; 17(11):1075-84. PubMed ID: 26212528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
